Company Overview
Quantum-Si incorporated operates within the healthcare sector as a specialized entity in the medical devices industry, focusing on the development of proprietary, universal, and single-molecule detection platforms for proteomics. The company's core mission is to enable next-generation protein sequencing through the provision of Platinum and Platinum Pro NGPS instruments designed for single-molecule, amino acid level resolution. As of the latest reporting period, the organization maintains a market capitalization of $187.16M and employs 145 individuals to execute its research and development objectives. With annual revenue recorded at $2.44M over the trailing twelve months, the company presents a small-cap profile that suggests it is still in a developmental phase where revenue generation is secondary to technological advancement and platform validation. This limited revenue base relative to the market cap indicates that the current valuation is heavily influenced by the potential future utility of its single-molecule detection technology rather than established cash-flowing operations.
Financial Health
The company reported revenue of $2.44M for the trailing twelve months, yet this revenue generated a net income of -$101,339,000 and an EBITDA of -$92,594,000. The substantial negative gap between the positive revenue figure and the large negative net income reveals a cost structure characterized by significant operating expenses that far exceed current sales, likely driven by heavy investment in R&D and platform development. Free cash flow stands at -$45,797,000, indicating that the company is consuming cash reserves to fund its operations and growth initiatives rather than generating liquidity from its core business activities. Gross margin is calculated at 47.3%, suggesting that the cost of goods sold for its instruments is well-controlled relative to sales prices, while the operating margin of -4677.2% and profit margin of 0.0% highlight severe operational inefficiencies or high fixed cost burdens not yet offset by scale. The balance sheet shows a cash position of $162.91M against total debt of $4.17M, resulting in a debt-to-equity ratio of 1.89. Despite the presence of leverage indicated by the debt-to-equity ratio, the massive cash hoard suggests the balance sheet is fundamentally solvent, though the high leverage ratio signals that equity has been diluted or debt utilization is aggressive relative to the small equity base. The current ratio is reported at 7.64, which indicates a highly conservative stance on short-term liquidity as current assets significantly outweigh current liabilities. Return on equity is -46.5% and return on assets is -24.6%, metrics that reveal management is currently generating negative returns on the capital invested in the company due to the lack of profitability.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of earnings, while the forward P/E is -2.34, implying that the market prices the stock based on anticipated future earnings rather than historical performance. The price-to-book ratio is 0.85, indicating that the market values the company at approximately 85% of its net asset value, which suggests a discount relative to the underlying book value of the firm's assets. The price-to-sales ratio is an exceptionally high 76.83, and the EV/EBITDA is -0.31, suggesting that traditional valuation multiples are distorted by the lack of earnings and that investors are pricing in significant future growth expectations or strategic value not reflected in current financial statements. The stock has traded between a 52-week high of $3.10 and a 52-week low of $0.83, meaning the current price sits in the lower portion of this historical range relative to the peak performance of the last year. The beta value is 3.08, which means the stock's price volatility is more than three times that of the broader market, indicating extreme sensitivity to market movements and higher risk for investors compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is -62.2%, while earnings growth is N/A, indicating that the company is currently contracting in terms of sales and has no established earnings trajectory to measure against. The negative revenue growth implies that the company is either in a market contraction phase or still scaling its customer base to reach profitability, meaning earnings cannot grow faster than revenue because there are no positive earnings to grow. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, choosing instead to retain all capital to fund its proprietary technology development and operational needs. This reinvestment strategy aligns with the company's life sciences focus, where funding next-generation protein sequencing capabilities takes precedence over returning capital to shareholders. The overall growth and income profile is defined by a contraction in revenue, a lack of dividend income, and a reliance on external capital or cash reserves to sustain operations until the single-molecule detection platform achieves commercial scale.